OSI-906

Phase 1Completed
1 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Advanced Solid Tumors

Conditions

Advanced Solid Tumors

Trial Timeline

Jun 18, 2007 → Mar 19, 2012

About OSI-906

OSI-906 is a phase 1 stage product being developed by Astellas Pharma for Advanced Solid Tumors. The current trial status is completed. This product is registered under clinical trial identifier NCT00514007. Target conditions include Advanced Solid Tumors.

What happened to similar drugs?

16 of 20 similar drugs in Advanced Solid Tumors were approved

Approved (16) Terminated (1) Active (4)
ApatinibTabletsJiangsu Hengrui MedicineApproved
letrozoleJiangsu Hengrui MedicineApproved
FulvestrantAstraZenecaApproved
Zoladex and CasodexAstraZenecaApproved
GefitinibAstraZenecaApproved
Alpelisib + FulvestrantNovartisApproved

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT00924989Phase 3Completed
NCT00514306Phase 1Completed
NCT00514007Phase 1Completed

Competing Products

20 competing products in Advanced Solid Tumors

See all competitors
ProductCompanyStageHype Score
mRNA-4359ModernaPhase 2
0
mRNA-4106ModernaPhase 1
0
AK-105AkesoPhase 1
29
AFM24 + Atezolizumab 840 MG in 14 ML InjectionAffimedPhase 1/2
14
EXS21546BiotrialPhase 1/2
14
SY-1365 (Part 1) + Carboplatin + Fulvestrant + SY-1365 (Cohort 2) + SY-1365 (Cohort 5) + SY-1365 (Part 2 Single Agent)Syros PharmaceuticalsPhase 1
11
Necitumumab + Gemcitabine + CarboplatinEli LillyPhase 2
27
Pemetrexed + Erlotinib + Pemetrexed + ErlotinibEli LillyPhase 2
35
NBTXR3NanobiotixPhase 1/2
33
pegfilgrastim + LY2523355Eli LillyPhase 1
29
SON-1010Sonnet BioTherapeuticsPhase 1
27
SON-1010Sonnet BioTherapeuticsPhase 1/2
18
BT1718Bicycle TherapeuticsPhase 1/2
22
Zentalis + GemzarZentalis PharmaceuticalsPhase 2
29
IMC-18F1Eli LillyPhase 1
29
Tadalafil + GemcitabineEli LillyPhase 1
29
OKI-179OnKure TherapeuticsPhase 1
19
OKI-219 + Fulvestrant + Trastuzumab + Tucatinib + Atirmociclib + RibociclibOnKure TherapeuticsPhase 1
26
LY3499446 + Abemaciclib + Cetuximab + Erlotinib + DocetaxelEli LillyPhase 1/2
24
LY3434172Eli LillyPhase 1
21